Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Oct 31;14(5):e0061823.
doi: 10.1128/mbio.00618-23. Epub 2023 Sep 19.

Early antibody treatment, inflammation, and risk of post-COVID conditions

Kelly A Gebo  1 , Sonya L Heath  2 , Yuriko Fukuta  3 , Xianming Zhu  4 , Sheriza Baksh  5 , Allison G Abraham  6 , Feben Habtehyimer  1 , David Shade  5 , Jessica Ruff  4 , Malathi Ram  7 , Oliver Laeyendecker  8 , Reinaldo E Fernandez  1 , Eshan U Patel  5 , Owen R Baker  1 , Shmuel Shoham  1 , Edward R Cachay  9 , Judith S Currier  10 , Jonathan M Gerber  11 , Barry Meisenberg  12 , Donald N Forthal  13 , Laura L Hammitt  7 , Moises A Huaman  14 , Adam Levine  15 , Giselle S Mosnaim  16 , Bela Patel  17 , James H Paxton  18 , Jay S Raval  19 , Catherine G Sutcliffe  5   7 , Shweta Anjan  20 , Thomas Gniadek  21 , Seble Kassaye  22 , Janis E Blair  23 , Karen Lane  24 , Nichol A McBee  24 , Amy L Gawad  24 , Piyali Das  24 , Sabra L Klein  25 , Andrew Pekosz  25 , Evan M Bloch  4 , Daniel Hanley  24 , Arturo Casadevall  25 , Aaron A R Tobian #  4 , David J Sullivan #  25 ; CSSC-004 Consortium
Affiliations
Randomized Controlled Trial

Early antibody treatment, inflammation, and risk of post-COVID conditions

Kelly A Gebo et al. mBio. .

Erratum in

  • Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions".
    Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ; CSSC-004 Consortium. Gebo KA, et al. mBio. 2024 Jan 16;15(1):e0297923. doi: 10.1128/mbio.02979-23. Epub 2023 Dec 14. mBio. 2024. PMID: 38095433 Free PMC article. No abstract available.

Abstract

Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

Keywords: COVID-19; COVID-19 serotherapy; chemokines; cytokines; interleukin-6; post-COVID condition (PCC); post-acute sequelae of COVID (PASC).

PubMed Disclaimer

Conflict of interest statement

See Acknowledgments for conflicts of interest.

Figures

Fig 1
Fig 1
Study population.
Fig 2
Fig 2
Trajectory of the cytokines during study period. Abbreviations: PCC, post-COVID-19 condition; SCR, screening visit; D14, day 14 visit; D90, day 90 visit. Note: each dot represents a sample, and each line represents a person.
Fig 3
Fig 3
Comparison of cytokines at screening between study participants with PCC and without PCC. PCC, post-COVID-19 condition. Note: P values were determined by Wilcoxon rank sum test. *IL-6 was significantly different after adjusting multiple comparison using Benjamini-Hochberg correction with a false discovery rate of 0.05.
See this image and copyright information in PMC

Comment in

References

    1. Centers for Disease Control and Prevention . COVID data tracker. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 11 March 2023
    1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition . 2022. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22:e102–e107. doi: 10.1016/S1473-3099(21)00703-9 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . Long COVID or post-COVID conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects. Accessed 11 March 2023
    1. Centers for Disease Control and Prevention . Post-COVID conditions: Overview for Healthcare providers. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-c.... Accessed 11 March 2023
    1. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P, Chinchilli VM. 2021. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568 - DOI - PMC - PubMed

Publication types